Hydrochloric Acid

Hydrochloric Acid

SCHEMBL6660435

Cl.NC(CCO)(CCO)CCO

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148930 0.96 MEN1 (0.47) MEN1LMNAKMT2AALDH1A1TSHR
Water SCHEMBL1204724 0.92 MEN1 (0.44) MEN1LMNAKMT2AALDH1A1TSHR
Bromide SCHEMBL15820403 0.92 MEN1 (0.44) MEN1LMNAKMT2AALDH1A1TSHR
Hydrochloric Acid SCHEMBL11315659 0.87 ALDH1A1 (0.39) MEN1LMNAKMT2AALDH1A1TSHR
Tromethamine SCHEMBL1933899 0.86 MEN1 (0.67) MEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL2138443 0.86 MEN1 (0.56) MEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL8432627 0.86 MEN1 (0.56) MEN1LMNAKMT2A
SCHEMBL5056997 0.83 LMNA (0.37) MEN1LMNAKMT2AALDH1A1TSHR
SCHEMBL2351528 0.83 MEN1 (0.37) MEN1LMNAKMT2A
Bicarbonate SCHEMBL8995795 0.83 ARG2 (0.39) MEN1LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4204609-B1 COMPOSITIONS AND METHODS FOR THE ELECTRODEPOSITION OF NANOTWINNED COPPER MACDERMID ENTHONE INC (US) 2026-05-27 EP claimed
US-20260078517-A1 COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION MACDERMID ENTHONE INC (US) 2026-03-19 US claimed
US-20240318342-A1 COMPOSITIONS AND METHODS FOR THE ELETRODEPOSITION OF NANOTWINNED COPPER MACDERMID ENTHONE INC. 2024-09-26 US claimed
WO-2024081584-A1 COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION MACDERMID ENTHONE INC. (US) 2024-04-18 WO claimed
US-20240110306-A1 Compositions and Methods for the Electrodeposition of Nanotwinned Copper MACDERMID ENTHONE INC (US) 2024-04-04 US claimed
US-11873568-B2 Compositions and methods for the electrodeposition of nanotwinned copper MACDERMID ENTHONE INC. (US) 2024-01-16 US claimed
CN-115781843-A Water-based flame-retardant treating agent and preparation method thereof 贵州洪乘宇科技有限责任公司 2023-03-14 CN claimed
US-20220298665-A1 Compositions and Methods for the Electrodeposition of Nanotwinned Copper MACDERMID ENTHONE INC (US) 2022-09-22 US claimed
US-11384446-B2 Compositions and methods for the electrodeposition of nanotwinned copper MACDERMID ENTHONE INC. (US) 2022-07-12 US claimed
US-5242463-A Fibers, threads, linters, roving, fabrics, yarns, slivers and paper THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1993-09-07 US claimed
EP-4204609-B1 COMPOSITIONS AND METHODS FOR THE ELECTRODEPOSITION OF NANOTWINNED COPPER MACDERMID ENTHONE INC (US) 2026-05-27 EP disclosed
US-20260078517-A1 COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION MACDERMID ENTHONE INC (US) 2026-03-19 US disclosed
EP-4567075-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2025-06-11 EP disclosed
US-20240318342-A1 COMPOSITIONS AND METHODS FOR THE ELETRODEPOSITION OF NANOTWINNED COPPER MACDERMID ENTHONE INC. 2024-09-26 US disclosed
EP-4381120-A1 COMPOSITIONS AND METHODS FOR THE ELECTRODEPOSITION OF NANOTWINNED COPPER MacDermid Enthone Inc. (US) 2024-06-12 EP disclosed
US-5242463-A Fibers, threads, linters, roving, fabrics, yarns, slivers and paper THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1993-09-07 US disclosed
EP-0365595-A4 AFFINITY REMOVAL OF CONTAMINATING SEQUENCES FROM RECOMBINANT CLONED NA USING CAPTURE BEADS. DU PONT (US) 1990-06-05 EP disclosed
EP-0365595-A1 AFFINITY REMOVAL OF CONTAMINATING SEQUENCES FROM RECOMBINANT CLONED NA USING CAPTURE BEADS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-05-02 EP disclosed
WO-1988010313-A1 AFFINITY REMOVAL OF CONTAMINATING SEQUENCES FROM RECOMBINANT CLONED NA USING CAPTURE BEADS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-12-29 WO disclosed
US-4264364-A A COMPLEX OF A FRIEDEL-CRAFTS HALIDE WITH AN ORGANIC COMPOUND COMPRISING A QUATERNARY AMMONIUM, A PHOSPHONIUM, A SULFONIUM, OR AN ORTHO SILICATE COMPOUND INDIAN HEAD INC. (US) 1981-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078517-A1 COMPOSITION AND METHOD FOR NANOTWINNED COPPER FORMATION AOC2, HCN2, STMN2 MEN1 979/4885LMNA 3174/4885KMT2A 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.